New Conviva Data Shows Streaming Platforms Holding Onto 2020 Pandemic Gains; International Markets Surging
11.8.2021 16:00:00 EEST | Business Wire | Press release
The streaming explosion, which hit its apex during the Covid-induced lockdowns in Q2 2020, is here to stay according to new data from Conviva, the intelligence cloud for streaming media. Conviva’s Q2 2021 State of Streaming report revealed streaming viewing time worldwide grew 13% in Q2 2021, as compared to Q2 2020. Despite a 7% decline in streaming viewing in April, North America still saw a 2% increase in streaming viewing in Q2 2021, compared to the same time last year. Other regions saw even bigger spikes in time spent streaming with Africa growing 79% and South America growing 192% year over year driven by the launch of new services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210811005256/en/
Q2 2021 State of Streaming from Conviva (Graphic: Business Wire)
In tandem with increased viewership, the quality of streaming ads also improved significantly in Q2 2021. Only 16% of ads represented missed opportunities as they went unfilled or failed to play as expected, down from 37% the previous quarter. While total ad attempts dropped 8% from Q1 to Q2 2021, more attempts were successful, resulting in a 4% increase overall in ad impressions. What’s more, in Q2 2021, viewers had a better experience with ads as they spent 31% less time waiting for ads to play and ad duration decreased 3% to 27 seconds.
“As the global streaming industry grows and competition becomes even more intense, consumer expectations for a superior streaming experience – premium content, consistent performance and high-quality ad creative – will only continue to rise,” said Keith Zubchevich, CEO, Conviva. “The publishers and advertisers that can meet or exceed these expectations will be rewarded with continued growth; however, failing to address any aspect of the viewing experience could spell disaster.”
Device Fragmentation; Roku Still Dominates
Big screens, including connected TV devices, smart TVs and gaming consoles, remained the dominant way to stream in Q2 2021, commanding 73% of global viewing time, down just 1% from Q2 2020 even as consumers spent less time home bound. Mobile phones captured that 1% share, growing from 10% in Q2 2020 to 11% in Q2 2021. While smart TVs continued their meteoric rise, up 46%, and connected TV devices saw moderate growth, up 5%, gaming consoles were the lone big screen streaming device to tally a significant decrease, down 14%. Among connected TV devices, Roku maintained its dominance with 31% global share of big screen viewing time, but dropped slightly in share as smart TV-only devices including Samsung TV, LG TV, Android TV, and Vizio TV each increased 1-2%.
Top Streaming Shows Being Discussed on Social
Streaming services are beginning to realize the immense value of social platforms as they promote their content and engage with consumers. Grey’s Anatomy, which promotes its streaming availability on Hulu, had the most cross-platform engagements on social media in Q2 2021, closely followed by Netflix’s Spanish-language drama Elite. Among new originals, Loki claimed the top social engagement spot for Disney+ at number four on Conviva’s list of the top streaming shows by social media engagement. Netflix was the streaming service most successfully driving engagements for its shows on social media with six shows noted on the list, followed by The CW with four of the top 25 shows.
The Fortune 500 and Social Videos
In addition to advertising on linear and streaming, the largest companies in the world continue to leverage video on social platforms as a way to engage with their customers. According to a Conviva analysis of the Fortune 500, McDonald’s, Netflix, Nike, Apple and Facebook all claimed top social spots in Q2 2021. Netflix tallied the most social media videos, most video views and highest total cross-platform engagements, while Apple had the highest average engagements per video and highest average engagements per post for the quarter. McDonald’s collaboration with the K-pop group BTS drove millions of engagements in Q2 2021, securing it the top spot for average cross-platform engagement rate for any brand with more than fifteen thousand followers.
To download the full report, visit: www.conviva.com/state-of-streaming
Methodology
Data for Conviva’s State of Streaming report was primarily collected from Conviva’s proprietary sensor technology currently embedded in 3.3 billion streaming video applications, measuring in excess of 500 million unique viewers watching 180 billion streams per year with nearly 2 trillion real-time transactions per day across more than 180 countries. Year-over-year comparisons were normalized at the customer level for accurate representations of industry growth. The social media data consists of data from over 2000 accounts, over 5 million posts, 12.5 billion video views and over 35 billion engagements across Facebook, Instagram, Twitter and YouTube.
About Conviva
Conviva is the intelligence cloud for streaming media. Powered by our patented Stream Sensor™ and Stream ID™, our real-time platform enables marketers, advertisers, technology teams and customer care teams to build, engage and monetize their audiences. Conviva is dedicated to supporting brands like CCTV, DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock the incredible opportunity in streaming media. Today our platform processes nearly 2 trillion streaming data events daily, supporting more than 500 million unique viewers watching 180 billion streams per year across 3.3 billion applications streaming on devices. Conviva ensures digital businesses of all sizes can stream better—every stream, every screen, every second. To learn more, visit www.conviva.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005256/en/
Contact information
Paula Winkel, pr@conviva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
